Oregon State University

Transferrin Receptor-Targeted ASOs Show Promise in Crossing the Blood-Brain Barrier

6 months ago

• Researchers have developed antisense oligonucleotides (ASOs) conjugated with a transferrin receptor (TfR)-targeting antibody fragment for enhanced brain delivery. • Intravenous administration of these TfR-ASO conjugates in mice demonstrated effective ASO distribution throughout the brain. • The TfR-ASO conjugates led to significant target mRNA reduction in the brain, showcasing their potential for treating neurological disorders. • This targeted delivery approach may improve the efficacy and reduce systemic exposure of ASO therapeutics for CNS diseases.

AI-Powered Saliva Test Offers Personalized Epilepsy Management

8 months ago

• Oregon State University researchers are developing an AI-driven saliva test to optimize anti-epileptic drug (AED) dosing for epilepsy patients. • The device aims to provide rapid, at-home monitoring of AED levels, overcoming the limitations of traditional blood tests. • The AI component will help to interpret complex saliva composition and personalize drug dosages based on individual patient needs and reported side effects. • The system will wirelessly transmit data to doctors, enabling timely adjustments to medication and improved seizure control.

Dog Aging Project Seeks Canine Volunteers for Longevity Research

10 months ago

• The Dog Aging Project (DAP) is a five-year study aiming to understand aging in dogs, potentially benefiting human health as well. • Researchers seek diverse canine participants, including large breeds, working dogs, and puppies, to study genetic and environmental factors. • A clinical trial within the DAP investigates rapamycin's effect on canine lifespan and healthspan, building on promising results in mice. • Dog owners can nominate their dogs at DogAgingProject.org, contributing to a large-scale community science effort with global research impact.

CBD Shows Promise in Curbing SARS-CoV-2 Replication, Clinical Trials Needed

3 years ago

• Early research suggests CBD may help curb SARS-CoV-2 replication in infected cells, warranting further investigation through rigorous clinical trials. • Studies indicate CBD acts post-infection, blocking virus replication, while THC and other cannabinoids do not show the same antiviral effects. • Researchers emphasize that current evidence does not support self-medication with CBD and highlight the importance of vaccines and antibody drugs. • Clinical trials are underway to assess CBD's efficacy in treating COVID-19, with challenges in enrolling patients due to milder Omicron cases.